Association of Anticholinergic Burden With Onset of Delirium in Older Adults With Alzheimer Dementia:

Alzheimer Disease Clinical Trial

Official title:

Association of Anticholinergic Burden With Onset of Delirium in Older Adults With Alzheimer Dementia: A Retrospective Cohort Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05055895
• Other study ID #: 2020-383
• Status: Recruiting
• Start date: January 1, 2005
• Est. completion date: December 2022

Study information

• Verified date: September 2021
• Source: Gulhane Training and Research Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Drugs with anticholinergic properties are commonly prescribed to older persons despite growing evidence of their significant adverse effects. However, limited data are available concerning their contribution to time of onset of delirium. This study aimed to determine the potential association of higher anticholinergic burden to early-onset of delirium superimposed dementia in the older adult.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 450
• Est. completion date: December 2022
• Est. primary completion date: June 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

• 65 years and older and diagnosis or fellow-up of Alzhemier dementia in outpatient clinic.

Exclusion Criteria:

• The patients with a history of other than Alzhemier dementia or neurodegenerative disease (epilepsy, multiple sclerosis, Parkinson disease, etc.), terminal illness (malignancy, advanced organ failure) were excluded.

Related Conditions & MeSH terms

• Alzheimer Disease
• Anticholinergic Adverse Reaction
• Delirium
• Dementia

Intervention

Drug:
• Anticholinergic burden
The anticholinergic burden (ACB) was assessed using the Anticholinergic Burden Scale. Higher ACB was described as equal or higher than 1.

Locations

Country	Name	City	State
Turkey	Gulhane training and research hospital	Ankara

Sponsors (1)

Lead Sponsor	Collaborator
Gulhane Training and Research Hospital

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time onset of delirium superimposed dementia	First attack of delirium onset	12 month